Cartesian Therapeutics, Inc. RNAC
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-10.08
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $2.8M | -$130.3M | — | -$79.4M | -$126.2M |
| 2024 | $38.3M | -$77.4M | — | -$32.8M | -$6.8M |
| 2023 | $26.0M | -$219.7M | — | -$51.4M | -$440.2M |
| 2022 | $110.8M | $35.4M | — | -$32.8M | $93.8M |
| 2021 | $85.1M | -$25.7M | — | -$61.5M | $22.5M |
| 2020 | $16.6M | -$68.9M | — | $34.1M | -$18.0M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -10.08 (distress)
- Working capital / assets 0.386
- Retained earnings / assets -2.774
- EBIT / assets -0.484
- Equity / liabilities -0.299
Source: SEC EDGAR filings · CIK 0001453687 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.